Rasmussen, Daniel Guldager Kring
Hansen, Michael K.
Blair, Joseph
Jatkoe, Timothy A.
Neal, Bruce
Karsdal, Morten A.
Genovese, Federica
Article History
Received: 12 May 2022
Accepted: 7 October 2022
First Online: 28 November 2022
Declarations
:
: The study was conducted according to the ethical principles put forth in the Declaration of Helsinki. All participants provided written informed consent, and the study protocol was approved by the Institutional Review Boards and ethics committees of each participating site.
: Not applicable.
: DGKR, FG and MAK are full-time employees at Nordic Bioscience. Nordic Bioscience is a privately-owned, small–medium size enterprise partly focused on the development of biomarkers. None of the authors received fees, bonuses or other benefits for the work described in the manuscript. DGKR, MAK, and FG hold stocks in Nordic Bioscience. The patent for the ELISA used to measure ETP levels is owned by Nordic Bioscience. The funder provided support in the form of salaries for authors DGKR, JB, FG and MAK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. TJ and MKH are full-time employees of Janssen Research and Development, LLC. BN has received research support and has served as a consultant and speaker for Janssen, with all fees paid to his employer, and interacts regularly on a nonfinancial basis with multiple large corporations in the pharmaceutical industry, the food processing industry, and the quick service restaurant industry in Australia and overseas. No other potential conflicts of interest relevant to this article were reported.